STING1/TMEM173 recombinant proteins and antibodies

STING1 (Stimulator of Interferon Genes 1), also known as STING or TMEM173, is a key adaptor protein located on the endoplasmic reticulum membrane, playing a central role in innate immune signaling. Upon recognition of cytosolic DNA, cGAS (cyclic GMP-AMP synthase) produces the second messenger cGAMP, which activates STING, leading to the induction of type I interferons and pro-inflammatory cytokines that drive antiviral and antitumor immune responses.
Because STING acts as a critical bridge between innate and adaptive immunity, it has become a major focus in cancer immunotherapy and infectious disease research. Current drug development mainly targets two directions: STING agonists, designed to boost antitumor immunity by inflaming the tumor microenvironment and activating dendritic cells and cytotoxic T cells; and STING inhibitors, aimed at treating autoimmune disorders caused by aberrant STING activation, such as SAVI (STING-associated vasculopathy with onset in infancy).

Globally, leading players include Merck & Co. and Novartis, which are investigating STING agonists in combination with immune checkpoint inhibitors. Hoth Therapeutics and Roche are advancing STING inhibitors for inflammatory diseases. Companies like iTeos Therapeutics and Aduro Biotech (now part of Chinook Therapeutics) have developed various small-molecule and cyclic dinucleotide (CDN) STING agonists. In China, biotech firms such as BeiGene, Hengrui Pharma, and Junshi Biosciences are also actively exploring STING pathway modulators, aiming to expand its therapeutic potential in oncology and antiviral applications.

To assist in the development of STING1-targeted small molecule drugs, DIMA BIOTECH can now provide full-length STING1 recombinant membrane protein developed by its nanodisc membrane protein platform. STING1 nanodisc is an optimal solution for screening small molecules targeting DTING1 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a STING1 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.